Global BREO Ellipta Drugs Market Report and Forecast 2024-2032

BREO Ellipta Drugs Market Outlook

The global BREO ellipta drugs market is driven by the growing chronic obstructive pulmonary disease drugs market, which is likely to grow at a rate of 4.5% during the forecast period of 2024-2032. The prevalence of these respiratory disease is expected to rise significantly over the coming years due to rising pollution levels, along with other factors.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

BREO Ellipta Drugs Market: Introduction and Insights

The pharmaceutical market for asthma and other respiratory diseases has increased by manifolds in the past few years due to the poor air quality across majority of the region. The BREO ellipta drug is one such drug and is approved for asthma patients over the age of 18 years. It is a prescription only powder inhaler which is used for one inhalation for one time each day to ease and control the symptoms of asthma to a significant extent. It helps the breathing process and controls wheezing. 

The drug contains vilanterol, which is a long-acting beta2-adrenergic agonist (LABA) medicine and can be fatal if used alone. This is why BREO contains a combination of inhaled corticosteroid (ICS) called fluticasone and a long-acting beta2-adrenergic agonist, which reduces the risk of any fatal effects. Fluticasone helps in reducing the swelling in the lungs. On the other hand, Vilanterol aids in the relaxation of muscles around the airways and can ease the process of breathing. While the drug is extremely effective if used regularly as per the doctor’s prescription, it needs to be used responsibly and not for sudden asthma attacks as it does not work as fast as a rescue inhaler.

Along with asthma patients, the BREO ellipta drug is also used in patients suffering from any other lung diseases like chronic obstructive pulmonary diseases (COPD) like chronic bronchitis and emphysema.

The drug also poses the threats of multiple side-effects. Some of these potential side-effects include choking, wheezing, fast or pounding heartbeats or any sort of pounding in the neck or ears, sores or white patches in the mouth and throat, pain when swallowing, fever, chills, cough with yellow or green mucus, blurred vision, eye pain, or seeing halos around lights, high blood sugar, increased thirst and urination, frequent cramps, constipation, muscle weakness or limp feeling, signs of a hormonal disorders. 

BREO Ellipta Drugs Market Segmentations

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The market can be divided on the basis of indication type, mode of administration, distribution channel, and major regions.

Market Breakup by Indication Type

• Chronic Obstructive Pulmonary Disease (COPD)

• Cystic Fibrosis

• Chronic Bronchitis

• Asthma

• Others

Market Breakup by Mode of Administration

• Dry Powder Inhaler

• Respimat Soft Mist Inhaler

• Pressurized Metered Dose Inhaler

• Nebulizers

• Others

Market Breakup by Distribution Channel

• Hospital Based Pharmacies

• Online Pharmacies

• Retail Pharmacies

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

BREO Ellipta Drugs Market Scenario and Epidemiology of Respiratory Disorders

The BREO Ellipta drugs market has been on a rise, especially since the prevalence of respiratory disease increased since the coronavirus pandemic. It triggered the respiratory issues amongst the people across the globe.  The drug is still not affordable for a lot of people as most of the patients are from the rural areas. COPD affects more than 300 million people globally and about 3 million of these people are affected due to air pollution in households and more than 14% of these cases are caused due to the occupational environment and exposures. While most of the patients belong to rural areas, urban areas also witness significant exposure to COPD. In terms of smoking habit, more than 40% of the patients are people who have never smoked in their life.  

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the BREO Ellipta drugs market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• GSK plc

• Akros Pharma Inc

• Sun Pharmaceutical Industries Ltd

• Gilead Sciences, Inc.

• Abbott

• Genosco Inc.

Key Highlights of the Report